Gilead Sciences GILD Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's change in accrued liabilities?
- Gilead Sciences (GILD) reported change in accrued liabilities of -$702M in Q1 2026.
- How has Gilead Sciences's change in accrued liabilities changed year-over-year?
- Gilead Sciences's change in accrued liabilities decreased by 187.7% year-over-year, from -$244M to -$702M.
- What is the long-term trend for Gilead Sciences's change in accrued liabilities?
- Over 2 years (2021 to 2024), Gilead Sciences's change in accrued liabilities has grown at a -60.4% compound annual growth rate (CAGR), from $689M to $108M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.